| Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525)±anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies P Schöffski, DSW Tan, M Martín, M Ochoa-de-Olza, J Sarantopoulos, ... Journal for immunotherapy of cancer 10 (2), 2022 | 90 | 2022 |
| Food effect projections via physiologically based pharmacokinetic modeling: predictive case studies C Tistaert, T Heimbach, B Xia, N Parrott, TS Samant, F Kesisoglou Journal of pharmaceutical sciences 108 (1), 592-602, 2019 | 64 | 2019 |
| Ribociclib Bioavailability Is Not Affected by Gastric pH Changes or Food Intake: In Silico and Clinical Evaluations TS Samant, S Dhuria, Y Lu, M Laisney, S Yang, A Grandeury, ... Clinical Pharmacology & Therapeutics 104 (2), 374-383, 2018 | 60 | 2018 |
| Optimization of voriconazole therapy for the treatment of invasive fungal infections in adults N Mangal, IS Hamadeh, MJ Arwood, LH Cavallari, TS Samant, KP Klinker, ... Clinical Pharmacology & Therapeutics 104 (5), 957-965, 2018 | 50 | 2018 |
| Quantitative clinical pharmacology for size and age scaling in pediatric drug development: a systematic review TS Samant, N Mangal, V Lukacova, S Schmidt The Journal of Clinical Pharmacology 55 (11), 1207-1217, 2015 | 43 | 2015 |
| Ribociclib drug‐drug interactions: Clinical evaluations and physiologically‐based pharmacokinetic modeling to guide drug labeling TS Samant, F Huth, K Umehara, H Schiller, SV Dhuria, M Elmeliegy, ... Clinical Pharmacology & Therapeutics 108 (3), 575-585, 2020 | 21 | 2020 |
| Development and qualification of physiologically based pharmacokinetic models for drugs with atypical distribution behavior: a desipramine case study TS Samant, V Lukacova, S Schmidt CPT: Pharmacometrics & Systems Pharmacology 6 (5), 315-321, 2017 | 19 | 2017 |
| Current strategies to streamline pharmacotherapy for older adults JF Schlender, V Vozmediano, AG Golden, M Rodriguez, TS Samant, ... European Journal of Pharmaceutical Sciences 111, 432-442, 2018 | 18 | 2018 |
| Evaluation of absolute oral bioavailability and bioequivalence of ribociclib, a cyclin‐dependent kinase 4/6 inhibitor, in healthy subjects Y Ji, AM Abdelhady, TS Samant, S Yang, K Rodriguez Lorenc Clinical Pharmacology in Drug Development 9 (7), 855-866, 2020 | 14 | 2020 |
| Phase Ib dose-escalation/expansion trial of ribociclib in combination with everolimus and exemestane in postmenopausal women with HR+, HER2− advanced breast cancer A Bardia, S Modi, M Oliveira, J Cortes, M Campone, B Ma, L Dirix, ... Clinical Cancer Research 26 (24), 6417-6428, 2020 | 12 | 2020 |
| Pharmacokinetics of ribociclib in subjects with hepatic impairment TS Samant, S Yang, M Miller, Y Ji The Journal of Clinical Pharmacology 61 (8), 1001-1009, 2021 | 7 | 2021 |
| Abstract P1-19-37: Pharmacokinetic assessment of ribociclib, an oral CDK4/6 inhibitor, and the interaction with endocrine therapy partners in patients with advanced breast cancer Y Ji, T Samant, M Quinlan, A Chakraborty Cancer Research 80 (4_Supplement), P1-19-37-P1-19-37, 2020 | 5 | 2020 |
| Population pharmacokinetic modeling of acetaminophen protein adducts in adults and children S Jiang, K Madrasi, T Samant, C Lagishetty, V Vozmediano, A Chiew, ... The Journal of Clinical Pharmacology 60 (5), 595-604, 2020 | 4 | 2020 |
| population pharmacokinetics (PopPK) and exposure-response (ER) analysis of neutropenia Y Lu, PH Huang, R Zieba, TS Samant, S Dhuria, MR Elmeliegy American Conference on Pharmacometrics (ACoP), 2017 | 4 | 2017 |
| Ribociclib in combination with everolimus and exemestane in men and postmenopausal women with HR+/HER2-advanced breast cancer following progression on a CDK4/6 inhibitor … S Hurvitz, D Yardley, A Zelnak, A DeMichele, E Tan-Chiu, C Ma, T Small, ... CANCER RESEARCH 77, 2017 | 4 | 2017 |
| The personalization of drug therapy for elderly patients JF Schlender, AG Golden, TS Samant, CV Lagishetty, S Schmidt Developing Drug Products in an Aging Society: From Concept to Prescribing …, 2016 | 3 | 2016 |
| A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies CC Lin, E Garralda, P Schöffski, DS Hong, LL Siu, M Martin, M Maur, ... Oncoimmunology 13 (1), 2290787, 2024 | 1 | 2024 |
| Abstract PD5-11: Not presented A Bardia, DA Yardley, S Hurvitz, G Wright, R Moroose, C Ma, L Hart, ... Cancer Research 78 (4_Supplement), PD5-11-PD5-11, 2018 | 1 | 2018 |
| Abstract P1-14-05: Ribociclib dose recommendations for potential pharmacokinetic drug interaction and in special patient populations with organ impairment AM Abdelhady, TS Samant, A Chakraborty, C Germa, X Liu, KI Umehara, ... Cancer Research 78 (4_Supplement), P1-14-05-P1-14-05, 2018 | 1 | 2018 |
| Abstract CT197: Phase Ib study of LXH254 + trametinib (TMT) in patients (pts) with NRAS-mutant melanoma F de Braud, C Dooms, RS Heist, C Lebbe, M Wermke, D Planchard, ... Cancer Research 82 (12_Supplement), CT197-CT197, 2022 | | 2022 |
Stephan SchmidtAssociate Professor of Pharmacy, University of FloridaBestätigte E-Mail-Adresse bei cop.ufl.edu
